BioMarin Names Former Genentech CEO Ian Clark as Board Chair

Apr 22, 2026 05:33 UTC

BMRN

Short term

BioMarin Pharmaceutical Inc. has appointed Ian Clark to lead its board of directors following the retirement of Richard Meier. The transition is pending shareholder approval at the upcoming annual meeting on June 2.

Ian Clark appointed as Board Chair
Formal election set for June 2
Richard Meier retires after joining the board in 2006
Clark brings experience as former Genentech CEO (2010-2016)
After-hours stock price rose to $55.30

BioMarin Pharmaceutical Inc. (BMRN) announced on Tuesday the appointment of Ian Clark as the new Chair of the Board. The transition is scheduled to take effect immediately following the company's Annual Meeting on June 2, pending formal election by shareholders. Clark, who joined the BioMarin board in 2025, brings extensive biopharmaceutical industry expertise to the leadership role. Most notably, he served as the Chief Executive Officer of Genentech from 2010 to 2016, providing him with a deep operational background in drug development and commercialization. Clark succeeds Richard Meier, who is retiring after nearly twenty years of service to the company. Meier first joined the board in 2006 and has served as the Chair since 2023, overseeing a significant era of the company's corporate evolution. In the equity markets, BioMarin shares closed the regular session down 0.47% at $54.62. However, the stock saw a slight uptick in after-hours trading, rising 1.24% to reach $55.30.